Autologous Adipose Tissue Composition for Breast Augmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current soft tissue replacement methods face challenges with artificial fillers that lack metabolic activity and cause foreign body responses, and transplanted tissue methods experience significant volume loss due to inadequate blood supply, leading to tissue breakdown and the need for repeated procedures.
Innovation Solution
A composition comprising adipose tissue and a compound that promotes new blood vessel formation, such as those upregulating FGF-2 and VEGF, is administered to enhance the survival rate of transplanted tissue by establishing an adequate blood supply, thereby reducing tissue volume loss and improving long-term survival.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If artificial or alloplastic fillers are used for soft tissue replacement, then the procedure is simple and provides immediate volume, but the material lacks metabolic activity, does not become physiologically incorporated, and induces foreign body response leading to fibrous capsule formation
Solution Approach 1:
The invention changes the fundamental parameter of the implant material from inert synthetic polymer to living autologous adipose tissue. This biological material can metabolize, incorporate into host tissue, and support vascularization, thereby eliminating the foreign body response while maintaining the procedural simplicity of injection-based delivery.
Solution Approach 2:
The invention creates a composite system combining living adipose tissue cells with a supportive carrier matrix. This composite structure allows the biological material to maintain its metabolic activity while being delivered and positioned effectively through minimally invasive injection techniques, resolving both the simplicity and biocompatibility requirements.
2Object-affected harmful factors
If transplanted tissue is used for soft tissue replacement, then metabolic activity is present, but significant volume loss occurs due to inadequate blood supply, tissue necrosis, and poor survival
Solution Approach 1:
The invention performs preliminary action by pre-preparing adipose tissue in a controlled environment before implantation. The tissue is processed, potentially pre-vascularized or conditioned, and formulated in a way that enhances its survival prospects upon transplantation, thereby reducing necrosis and improving long-term viability.
Solution Approach 2:
The invention introduces an intermediary carrier system that facilitates the transition of living adipose tissue from donor site to recipient site. This intermediary structure provides temporary support, maintains tissue viability during transport and implantation, and promotes integration with host vasculature, thereby improving survival rates.
3Ease of operation
If artificial fillers are used, then the procedure is minimally invasive, but the fillers are rapidly reabsorbed requiring repeated procedures for long-term effects
Solution Approach 1:
The invention employs self-service by using autologous adipose tissue that can self-sustain through metabolic activity and self-renewal capabilities. The living tissue integrates with host vasculature and continues to function long-term without requiring additional injections or procedures, thereby providing durable results through the body's own biological processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach increases the survival rate of transplanted tissue by promoting angiogenesis, supporting the transplanted tissue with an adequate blood supply, and reduces the need for repeated procedures by maintaining tissue health and function over time.
Implementation Method 1
The growth of new blood vessels and associated vasculature or repair or remodeling of existing blood vessels and associated vasculature provides collateral circulation in and around an ischemic area, improves blood flow, and alleviates the symptoms caused by the ischemia.
Data Source
AI summary
The present specification discloses compositions and methods for use in breast augmentation procedures. The compositions include adipose tissue and compounds that upregulate both FGF-2 and VEGF, promote new blood vessel formation thereby reducing tissue volume loss and increasing survival rate of the adipose tissue when the composition is introduced into breast tissue.